Hosted on MSN1mon
Leerink raises 89bio stock target to $37 on NASH study optimism(NASDAQ:ETNB) to $37 from $34, while reiterating an Outperform ... data from a Phase 2b SYMMETRY study of efruxifermin (EFX) in NASH patients with compensated cirrhosis. The results demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback